3000 Bayport Drive
Suite 910
Tampa, FL 33607
United States
813-865-1125
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. John M. Stanton | Chairman, CEO, CFO & Principal Accounting Officer | S.O. | S.O. | 1963 |
Mr. Benedict Salvadore Maniscalco | Director of Clinical Research, Medical Director & Director | 87,5k | S.O. | 1942 |
Dr. Neva Ciftcioglu | Co-Founder, Director of Science & Scientific Advisor | S.O. | S.O. | S.O. |
Dr. E. Olavi Kajander | Chief Science & Research Officer and MD of Nanobac OY | S.O. | S.O. | S.O. |
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.
L’ISS Governance QualityScore de Nanobac Pharmaceuticals, Incorporated en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..